Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Drug Metabolism And Disposition

• Publication date

  2009-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.108.025494PMID 19773538
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles

  2008influential reference
• Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

  2008influential reference
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007cited by this paper
• Prediction of intestinal first-pass drug metabolism.

  2007cited by this paper
• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

  2007cited by this paper
• Comparison of different approaches to predict metabolic drug–drug interactions

  2007cited by this paper
• Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

  2006cited by this paper
• A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

  2006cited by this paper
• Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin

  2006cited by this paper
• The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers

  2005cited by this paper
• THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES

  2005cited by this paper
• AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS

  2005influential reference
• Alamethicin permeabilizes the plasma membrane and mitochondria but not the tonoplast in tobacco (Nicotiana tabacum L. cv Bright Yellow) suspension cells.

  2005cited by this paper
• In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: Qualitative relationships, quantitative predictions, and the rank‐order approach

  2005cited by this paper
• Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in healthy volunteers

  2004cited by this paper
• Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro

  2004influential reference
• Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.

  2004cited by this paper
• Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.

  2004cited by this paper
• Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.

  2004influential reference
• Troleandomycin-triazolam interaction in healthy volunteers: Pharmacokinetic and psychometric evaluation

  2004cited by this paper
• Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

  2004cited by this paper
• Cytochromes P450, drugs, and diseases.

  2003cited by this paper
• Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.

  2003cited by this paper
• Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent

  2003cited by this paper
• Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A.

  2003influential reference
• The Fluorescent Probe Bodipy-FL-Verapamil Is a Substrate for Both P-glycoprotein and Multidrug Resistance-related Protein (MRP)-1

  2002cited by this paper
• The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.

  2002cited by this paper
• A pilot evaluation of alfentanil‐induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans

  2001cited by this paper
• Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.

  2001influential reference
• CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.

  2000influential reference
• Effect of Metoprolol and Verapamil Administered Separately and Concurrently after Single Doses on Liver Blood Flow and Drug Disposition

  2000cited by this paper
• Effect of Clarithromycin on the Pharmacokinetics of Tolbutamide

  2000cited by this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000influential reference
• Clinical Pharmacokinetics of Clarithromycin

  1999cited by this paper
• Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

  1999cited by this paper
• Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.

  1999cited by this paper
• Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.

  1999cited by this paper
• Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes

  1999cited by this paper
• Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences

  1998cited by this paper
• Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.

  1998cited by this paper
• Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• In vitro approaches to predicting drug interactions in vivo.

  1998cited by this paper
• Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

  1998cited by this paper
• Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.

  1997influential reference
• Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.

  1997influential reference
• Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.

  1997cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996cited by this paper
• Possible Role of the Intestinal P‐450 Enzyme System in a Cyclosporine‐Clarithromycin Interaction

  1996cited by this paper
• Interaction between midazolam and clarithromycin: comparison with azithromycin.

  1996cited by this paper
• Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.

  1996cited by this paper
• A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism

  1996cited by this paper
• Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

  1995cited by this paper
• The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine

  1995cited by this paper
• Dose of midazolam should be reduced during diltiazem and verapamil treatments.

  1994cited by this paper
• A potentially hazardous interaction between erythromycin and midazolam.

  1993cited by this paper
• Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes.

  1993influential reference
• P‐glycoprotein‐mediated transcellular transport of MDR‐reversing agents

  1993cited by this paper
• Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine

  1992cited by this paper
• Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

  1991cited by this paper
• Selective inhibition of warfarin metabolism by diltiazem in humans.

  1991cited by this paper
• Effect of calcium channel blockers on theophylline disposition

  1988cited by this paper
• Erythromycin enhances the absorption of cyclosporin.

  1988cited by this paper
• Cyclosporin-erythromycin interaction in normal subjects.

  1987cited by this paper
• Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient.

  1987cited by this paper
• A pharmacokinetic drug interaction between erythromycin and triazolam.

  1986cited by this paper
• Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol.

  1985cited by this paper
• The pharmacological and pharmacokinetic properties of troleandomycin.

  1975cited by this paper

• A theoretical model for detecting drug interaction with awareness of timing of exposure

  2025cites this paper
• Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4

  2023cites this paper
• Case Study on Certara’s Simcyp PBPK Simulator to Eliminate Lengthy Clinical Trails

  2022cites this paper
• Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

  2021cites this paper
• Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance.

  2021cites this paper
• Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model

  2021cites this paper
• Herbal remedies, toxicity, and regulations

  2021cites this paper
• Numerical analysis of time-dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting

  2020influential citation
• Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes

  2020cites this paper
• Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants

  2020cites this paper
• Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes)

  2019cites this paper
• The Effect of Promiscuous Aggregation on in Vitro Drug Metabolism Assays

  2019cites this paper
• Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1

  2019influential citation
• Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

  2019cites this paper
• Predicting the pharmacokinetics of piperacillin and tazobactam in preterm and term neonates using physiologically based pharmacokinetic modeling

  2019cites this paper
• In Vitro Assessment of Potential for CYP-Inhibition-Based Drug–Drug Interaction Between Vonoprazan and Clopidogrel

  2018cites this paper
• A strategy for early-risk predictions of clinical drug–drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors

  2018cites this paper
• Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug–drug interaction potential of CYP3A4 substrates

  2018cites this paper
• Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids †

  2018cites this paper
• Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

  2018cites this paper
• Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies

  2018cites this paper
• PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

  2018cites this paper
• Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery.

  2017cites this paper
• Synthesis and In Vitro AMPK Activation of Cycloalkyl/Alkarylbiguanides with Robust In Vivo Antihyperglycemic Action

  2017cites this paper
• Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults

  2016cites this paper
• A physiologically based pharmacokinetic modeling approach to predict drug–drug interactions between domperidone and inhibitors of CYP3A4

  2016cites this paper
• Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma

  2016cites this paper
• Discovery of 2-(3,4-dichlorophenoxy)-N-(2-morpholin-4-ylethyl)acetamide: A selective σ1 receptor ligand with antinociceptive effect.

  2016cites this paper
• CYP Inhibition Methods

  2016cites this paper
• Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame

  2016cites this paper
• Pharmacological profile of N-(2,6-dichlorophenyl)-2-(4-methyl-1-piperidinyl)acetamide, a novel analogue of lidocaine.

  2016cites this paper
• DMD066902 162..171

  2016cites this paper
• Cytochrome P450 Inhibition

  2016cites this paper
• VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions

  2016cites this paper
• Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8.

  2015cites this paper
• Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements

  2015cites this paper
• Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOCTM) System

  2015cites this paper
• Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum is a CYP2D6 inhibitor of human, monkey, and dog isoforms

  2015cites this paper
• CYP3A4 inhibition by Psoralea corylifolia and its major components in human recombinant enzyme, differentiated human hepatoma HuH-7 and HepaRG cells

  2015cites this paper
• Physiologically Based Pharmacokinetic ( PBPK ) Modeling and Simulation Approaches : A Systematic Review of Published Models , Applications , and Model Verification s

  2015cites this paper
• Drug–Drug Interaction: From Bench to Drug Label

  2015cites this paper
• The role of drug metabolism in drug discovery and development : case ospemifene

  2015cites this paper
• Hepatocyte-Based Metabolism, Drug–Drug Interaction, and Toxicity Assays in Drug Discovery and Drug Development to Minimize Attrition

  2015cites this paper
• Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum is a CYP2D6 inhibitor of human, monkey, and dog isoforms

  2015cites this paper
• Guanfu Base A, an Antiarrhythmic Alkaloid of Aconitum coreanum, Is a CYP2D6 Inhibitor of Human, Monkey, and Dog Isoforms

  2015cites this paper
• DMD058297 1587..1595

  2014influential citation
• Synthesis, in vitro and in silico studies of a PPARγ and GLUT-4 modulator with hypoglycemic effect.

  2014cites this paper
• Human Liver Cytochrome P450 3A4 Ubiquitination

  2014cites this paper
• Exploring concepts of in vitro time-dependent CYP inhibition assays

  2014influential citation
• Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors

  2014cites this paper
• Synthesis of 2-{2-[(α/β-naphthalen-1-ylsulfonyl)amino]-1,3-thiazol-4-yl} acetamides with 11β-hydroxysteroid dehydrogenase inhibition and in combo antidiabetic activities.

  2014cites this paper
• Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes

  2014cites this paper
• Assessment of CYP3A4 Time-Dependent Inhibition in Plated and Suspended Human Hepatocytes

  2014cites this paper
• 2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected protozoan parasites.

  2014cites this paper
• A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data

  2014cites this paper
• Biomarkers and human hepatocytes.

  2014cites this paper
• ABSTRACTS FROM THE 10TH INTERNATIONAL ISSX MEETING

  2014cites this paper
• Consideration of the unbound drug concentration in enzyme kinetics.

  2014cites this paper
• Reversible mechanisms of enzyme inhibition and resulting clinical significance.

  2014cites this paper
• In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development.

  2014cites this paper
• Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach

  2013cites this paper
• Structure guided design of a series of sphingosine kinase (SphK) inhibitors.

  2013cites this paper
• Effect of Solvents on the Time-Dependent Inhibition of CYP3A4 and the Biotransformation of AZD3839 in Human Liver Microsomes and Hepatocytes

  2013cites this paper
• Discovery of Thiazolidine‐2,4‐Dione/Biphenylcarbonitrile Hybrid as Dual PPAR α/γ Modulator with Antidiabetic Effect: In vitro, In Silico and In Vivo Approaches

  2013cites this paper
• Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes

  2013influential citation
• Fluorescence-based screening of cytochrome P450 activities in intact cells.

  2013cites this paper
• DMD049114 343..352

  2013influential citation
• In vitro assessment of some traditional medications used in South Africa for pharmacokinetics drug interaction potential

  2013cites this paper
• Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

  2013cites this paper
• Dynamic Modeling of Cytochrome P450 Inhibition In Vitro: Impact of Inhibitor Depletion on IC50 Shift

  2013cites this paper
• DDI Risk Assessment and Evaluation in Pharmaceutical Development: Interfacing Drug Metabolism and Clinical Pharmacology

  2012cites this paper
• Pharmacokinetics/pharmacodynamics model-supported early drug development.

  2012cites this paper
• Predictions of CYP-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions

  2012cites this paper
• Time-Dependent Inhibition and Estimation of CYP3A Clinical Pharmacokinetic Drug-Drug Interactions Using Plated Human Cell Systems

  2012cites this paper
• Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions

  2012cites this paper
• Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

  2012cites this paper
• An Overview of the Evidence and Mechanisms of Herb–Drug Interactions

  2012cites this paper
• Microsoft Word-32394427-file00.docx

  2012cites this paper
• Microsoft Word-39738606-file00.docx

  2012cites this paper
• Time-Dependent Inhibition and Estimation of CYP3A Clinical Pharmacokinetic Drug-Drug Interactions Using Plated Human Cell Systems

  2012cites this paper
• The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions.

  2012cites this paper
• Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma

  2011influential citation
• Casopitant: In Vitro Data and SimCyp Simulation to Predict In Vivo Metabolic Interactions Involving Cytochrome P450 3A4

  2011influential citation
• CYP3A TIME DEPENDENT INHIBITION RISK ASSESSMENT VALIDATED WITH 400 REFERENCE DRUGS

  2011cites this paper
• Physiologically-based pharmacokinetics in drug development and regulatory science.

  2011cites this paper
• Kinetic characterization of rat hepatic uptake of 16 actively transported drugs

  2011cites this paper
• Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.

  2011cites this paper
• Microsoft Word-22828359-file00.docx

  2011cites this paper
• Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs

  2011cites this paper
• CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs

  2011influential citation
• Ubiquitin-dependent Proteasomal Degradation of Human Liver Cytochrome P450 2E1

  2011cites this paper
• Determination of Time-Dependent Inactivation of CYP3A4 in Cryopreserved Human Hepatocytes and Assessment of Human Drug-Drug Interactions

  2011influential citation
• Simulation of Clinical Drug-Drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs

  2011cites this paper
• Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors

  2010influential citation
• Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP 3 A Inhibitors

  2010influential citation
• Nociceptor Sensitization by Proinflammatory Cytokines And Chemokines

  2010cites this paper